RARE – Ultragenyx Pharmaceutical Inc.
Float Short %
8.52
Margin Of Safety %
Put/Call OI Ratio
0.46
EPS Next Q Diff
0.06
EPS Last/This Y
1.23
EPS This/Next Y
1.35
Price
29.79
Target Price
85.05
Analyst Recom
1.19
Performance Q
-16.14
Relative Volume
0.66
Beta
0.2
Ticker: RARE
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-07-25 | RARE | 27.34 | 0.63 | 0.11 | 72397 |
| 2025-07-28 | RARE | 27.6 | 0.61 | 0.28 | 73947 |
| 2025-07-29 | RARE | 27.68 | 0.60 | 0.05 | 74519 |
| 2025-07-30 | RARE | 27.14 | 0.60 | 0.64 | 74687 |
| 2025-07-31 | RARE | 27.4 | 0.60 | 0.08 | 75051 |
| 2025-08-01 | RARE | 28.36 | 0.60 | 0.32 | 75754 |
| 2025-08-04 | RARE | 28.44 | 0.59 | 0.40 | 75880 |
| 2025-08-05 | RARE | 28.91 | 0.59 | 0.47 | 76350 |
| 2025-08-06 | RARE | 28.08 | 0.59 | 0.83 | 76734 |
| 2025-08-07 | RARE | 27.81 | 0.59 | 0.25 | 80581 |
| 2025-08-08 | RARE | 27.55 | 0.56 | 0.27 | 80316 |
| 2025-08-11 | RARE | 27.47 | 0.56 | 25.42 | 80367 |
| 2025-08-12 | RARE | 28.07 | 0.57 | 0.14 | 80847 |
| 2025-08-13 | RARE | 28.95 | 0.56 | 0.38 | 81336 |
| 2025-08-14 | RARE | 29 | 0.56 | 23.50 | 81543 |
| 2025-08-15 | RARE | 29.69 | 0.56 | 0.40 | 81543 |
| 2025-08-18 | RARE | 29.69 | 0.47 | 0.42 | 44908 |
| 2025-08-19 | RARE | 29.13 | 0.48 | 0.32 | 45136 |
| 2025-08-20 | RARE | 29.36 | 0.48 | 0.29 | 45172 |
| 2025-08-21 | RARE | 29.6 | 0.47 | 0.03 | 45215 |
| 2025-08-22 | RARE | 29.77 | 0.46 | 0.07 | 45920 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-07-25 | RARE | 27.34 | 12.8 | - | -5.33 |
| 2025-07-28 | RARE | 27.62 | 12.8 | - | -5.33 |
| 2025-07-29 | RARE | 27.66 | 12.8 | - | -5.33 |
| 2025-07-30 | RARE | 27.14 | 12.8 | 0.9 | -5.33 |
| 2025-07-31 | RARE | 27.32 | 13.1 | -13.8 | -5.32 |
| 2025-08-01 | RARE | 28.44 | 13.1 | -34.4 | -5.32 |
| 2025-08-04 | RARE | 28.46 | 13.1 | -10.2 | -5.32 |
| 2025-08-05 | RARE | 28.92 | 13.1 | -19.5 | -5.32 |
| 2025-08-06 | RARE | 28.06 | 13.1 | 7.7 | -5.32 |
| 2025-08-07 | RARE | 27.83 | 9.6 | -5.3 | -5.32 |
| 2025-08-08 | RARE | 27.54 | 9.6 | -18.6 | -5.05 |
| 2025-08-11 | RARE | 27.40 | 13.7 | -21.8 | -5.08 |
| 2025-08-12 | RARE | 28.09 | 12.6 | -39.9 | -5.11 |
| 2025-08-13 | RARE | 28.97 | 13.6 | -42.9 | -5.11 |
| 2025-08-14 | RARE | 29.00 | 13.6 | -25.2 | -5.11 |
| 2025-08-15 | RARE | 29.69 | 13.6 | -38.5 | -5.06 |
| 2025-08-18 | RARE | 29.70 | 13.6 | -24.9 | -5.06 |
| 2025-08-19 | RARE | 29.12 | 13.6 | -13.3 | -5.06 |
| 2025-08-20 | RARE | 29.34 | 13.6 | -29.2 | -5.06 |
| 2025-08-21 | RARE | 29.52 | 13.6 | -27.9 | -5.06 |
| 2025-08-22 | RARE | 29.79 | 13.6 | -30.0 | -5.06 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-07-25 | RARE | -2.60 | 3.72 | 9.96 |
| 2025-07-28 | RARE | -2.60 | 3.50 | 9.96 |
| 2025-07-29 | RARE | -2.60 | 3.50 | 9.96 |
| 2025-07-30 | RARE | -2.60 | 3.50 | 9.96 |
| 2025-07-31 | RARE | -2.60 | 3.50 | 9.96 |
| 2025-08-01 | RARE | -2.60 | 3.50 | 9.96 |
| 2025-08-04 | RARE | -2.60 | 3.27 | 9.96 |
| 2025-08-05 | RARE | -2.60 | 3.27 | 9.96 |
| 2025-08-06 | RARE | -2.60 | 3.27 | 9.96 |
| 2025-08-07 | RARE | -2.60 | 3.27 | 9.96 |
| 2025-08-08 | RARE | -2.60 | 3.27 | 9.96 |
| 2025-08-11 | RARE | -2.55 | 3.23 | 9.77 |
| 2025-08-12 | RARE | -2.55 | 3.23 | 8.48 |
| 2025-08-13 | RARE | -2.55 | 3.23 | 8.48 |
| 2025-08-14 | RARE | -2.55 | 3.23 | 8.48 |
| 2025-08-15 | RARE | -2.51 | 3.23 | 8.49 |
| 2025-08-18 | RARE | -2.51 | 5.22 | 8.52 |
| 2025-08-19 | RARE | -2.39 | 5.22 | 8.52 |
| 2025-08-20 | RARE | -2.39 | 5.22 | 8.52 |
| 2025-08-21 | RARE | -2.39 | 5.22 | 8.52 |
| 2025-08-22 | RARE | -2.39 | 5.22 | 8.52 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.17
Avg. EPS Est. Current Quarter
-1.21
Avg. EPS Est. Next Quarter
-1.11
Insider Transactions
-2.39
Institutional Transactions
5.22
Beta
0.2
Average Sales Estimate Current Quarter
166
Average Sales Estimate Next Quarter
181
Fair Value
Quality Score
38
Growth Score
52
Sentiment Score
47
Actual DrawDown %
83.4
Max Drawdown 5-Year %
-85.2
Target Price
85.05
P/E
Forward P/E
PEG
P/S
4.7
P/B
18.93
P/Free Cash Flow
EPS
-5.53
Average EPS Est. Cur. Y
-5.06
EPS Next Y. (Est.)
-3.71
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-87.34
Relative Volume
0.66
Return on Equity vs Sector %
-377
Return on Equity vs Industry %
-364
EPS 1 7Days Diff
EPS 1 30Days Diff
0.27
EBIT Estimation
-30
Ultragenyx Pharmaceutical Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 1294
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701 that is in Phase 2 clinical trial for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Solid Biosciences Inc.; Regeneron; Abeona; and Arcturus Therapeutics Holdings Inc. The company was incorporated in 2010 and is headquartered in Novato, California.
stock quote shares RARE – Ultragenyx Pharmaceutical Inc. Stock Price stock today
news today RARE – Ultragenyx Pharmaceutical Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch RARE – Ultragenyx Pharmaceutical Inc. yahoo finance google finance
stock history RARE – Ultragenyx Pharmaceutical Inc. invest stock market
stock prices RARE premarket after hours
ticker RARE fair value insiders trading